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A B S T R A C T
OBjeCTive: Immunophenotype has been correlated with molecular aberrations in 
several studies. The aim of this study was the discovery of immunophenotypic fea-
tures related to mutations in AML and MDS patients connected to prognostic factors. 
Moreover, an effort to evaluate a method for the detection of the most common Nu-
cleophosmin (NPM1) mutations of exon12 and Internal Tandem Duplications (ITD) 
mutations of FLT3 gene by flow cytometry was performed.
MeThOd: Patients with de novo myeloid neoplasms [AML and MDS (AML-M3 pa-
tients were excluded)] were included. FLT3/ITD/TKD and NPM1 mutations were de-
tected by PCR and fragment analysis. The immunophenotypic analysis was performed 
by multi-dimensional flow cytometry (FC) with a standardized panel of monoclonal 
antibodies on peripheral blood or bone marrow samples. Nucleophosmin Antibody 
and CD135 were used for the mutations immunophenotypic detection.
ReSulTS: NPM1 and/or FLT3 mutations correlated with low or no expression of more 
immature cells markers such as CD34, CD117, HLADR, as well as higher expression 
of more mature markers such as CD11b. The higher expression of CD33 should be 
mentioned as well. The presence of NPM1mut and FLT3/ITD does not seem to be 
detectable by FC at least using these two monoclonal antibodies. The presence of 
CD7 aberrant lymphoid marker’s expression was associated with FLT3mut, NPM1wt 
genotype. CD56 or CD2 positivity was found only in patients’ samples negative for 
NPM1 and/or FLT3 mutations.
COnCluSiOnS: Certain immunophenotype findings including the presence of aber-
rant lymphoid markers may be indicative of the presence of mutations in NPM1 and 
FLT3 linked to prognosis.
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i n T R O d u C T i O n
Acute myeloid leukemia (AML) is an aggressive malig-
nancy of bone marrow stem cells and the most common type 
of acute leukemia (AL) in adults, accounting for about 80% 
of cases in this age group.1 AML is a clinically heterogeneous 
disease with variable cytogenetic abnormalities and molecular 
markers. The Karyotype of the leukemic cells is the most im-
portant predictor of response to the treatment and of patients’ 
survival.2,3 Gene abnormalities have a strong predictive power 
as well.4-6 Among these, high (≥0.5) FLT3-ITD allelic ratio 
has an unfavorable prognosis,7-9 whereas NPM1 gene muta-
tion with either absence or low (<0.5) FLT3-ITD allelic ratio 
carries a favorable10-13 prognosis.
Myelodysplastic syndromes (MDS) are clonal haemat-
opoietic disorders characterized by dysplasia and ineffective 
haematopoiesis in one or more lineages, increasing the risk 
(to approximately 30%) of leukemic evolution.14,15
Mutations in the gene of Nucleophosmin (NPM1) are the 
most frequent with great prognostic value in AML.16-19 NPM1 
mutations are usually characterized by a 4 base pair insertion 
at the terminal end of the exon 12 and occur in about 35% 
of adult AML.16,17 Mutations in NPM1 lead to aberrant cyto-
plasmic presence of the nucleophosmin protein.17,18 It seems 
that NPM1 mutations have a favorable prognostic value in the 
absence of FLT3/ITD mutations19,20 in patients with normal 
karyotype. Fms-like tyrosine kinase-3 (FLT3) is a class III 
tyrosine kinase receptor, whose relevant gene is located on 
chromosome 13q12.21-23 The most common mutation type in 
the FLT3 gene is internal tandem duplication (FLT3/ITD) of 
the region coding for the juxtamembrane (JM) domain of the 
FLT3 receptor. The length of the duplication in this region 
varies from 3 to 400 bases.25 About 20-30% of the patients with 
AML carry an FLT3/ITD mutation22,23 which is associated with 
poor prognosis.21,26 FLT3/ITD mutation has also been detected 
in MDS patients.24 The second most common mutation in 
the FLT3 gene is located in the activation loop of Tyrosine 
Kinase Domain (TKD). It is a point mutation at codon 835 
which involves aspartic acid and is usually related to a G to 
T substitution of the first nucleotide of the D835 codon.27-29,31 
Many studies have shown that FLT3/TKD mutations are also 
associated with poor prognosis. FLT3/TKD mutations are not 
so frequent and occur in about 7% and 3% of patients with 
AML and MDS respectively.30,31
Multiparameter flow cytometry (MFC) plays a major role 
in the diagnosis of AML and MDS32-34 and it is routinely used 
in clinical laboratories. Besides the great importance of the 
molecular features of acute leukemias, immunophenotypic 
study is very important and plays a major role in the diagno-
sis and the Minimal Residual Disease (MRD) monitoring of 
each patient.35,36 A discrete immunophenotype leads to severe 
suspicion for Acute Promyelocytic Leukemia (APL) diagnosis 
and to the molecular verification of it, this is why APL cases 
were not included in this study. Certain immunophenotype 
results have been correlated with other molecular aberra-
tions and prognosis in several studies,37,38 but the conclusions 
remain controversial. In addition, some efforts to detect 
molecular abnormalities through immunophenotypic detec-
tion of related protein expression have been reported with 
variable success.38,39-44
The aim of this study was the correlation of immunophe-
notypic features and mutations in AML and MDS patients 
as well as the discovery of related prognostic factors in the 
patients, so that as much information as possible is given by 
the immunophenotype to the molecular biology lab and to 
the clinical hematologists at the time of diagnosis. In addition, 
an effort to evaluate a method for the detection of NPM1 
mutations and FLT3/ITD mutations by flow cytometry was 
undertaken.
M A T e R i A l S  A n d  M e T h O d S
Patients included in the study were diagnosed with de 
novo AML or with primary MDS, according to the 2016 WHO 
classification. Patients with acute promyelocytic leukemia 
were excluded from the study. Peripheral blood (PB) or Bone 
marrow (BM) samples were obtained from 82 patients with 
AML and 12 with MDS before treatment. The study included 
37 females (39.3%) and 57 males (60.6%) with mean age 57.6 
years (range 19-88). Table 1 presents other relevant charac-
teristics of the patients included in the study.
All patients gave their consent to participate in the study 
after being informed of the purpose and the use of the results.
M O l e C u l A R  A n A ly S i S
FLT3/ITD/TKD and NPM1 mutations were detected by 
polymerase chain reaction (PCR). Genomic DNA was ex-
tracted from 107 mononuclear cells, isolated from peripheral 
blood or bone marrow samples by gradient centrifugation. The 
PCR mix for the detection of FLT3/ITD mutation contained 
in a total reaction of 25μl: 1x reaction buffer, 0.1mM dNTPs, 
1.5pmole of each primer (Forward: 5’-NED-CAATTTAG-
GTATGAAAGCCAGC-3’) and (Reverse 5’-CTTTCAG-
CATTTTGACGGCAACC-3’), 0.5μl Platinum TaqDNA 
Polymerase (Invitrogen), 1.5mM MgCl2 and 10ng of template. 
Initial Denaturation step was set at 94°C for 3 minutes, 
followed by 35 cycles of denaturation at 94°C for 20 seconds, 
annealing at 60°C for 20 seconds and extension at 72°C for 
20 seconds. Final extension was set at 72°C for 10 minutes. 
PCR products were run on 3130 Genetic Analyzer (Applied 
Biosystems) and analysis was performed on GeneMapper v4 
software. PCR product of FLT3 wild type (WT) showed only 
one fragment of 328 bp. Any additional fragment longer than 
the 328 bp was considered as mutant (Figure 1). The insertion 
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of tandem duplications into exon 11 and exon 12 ranged from 
3 to 400 bases.25 Similar results were found in our study. The 
FLT3/ ITD allelic ratio is calculated by dividing the peak area 
of FLT3 mut by the FLT3 wt peak area.
The 2017 European Leukemia Net (ELN) recommenda-
tions defined a cut-off value of 0.5 allelic ratio.45 A high allelic 
ratio (>0.5) is associated with poor prognosis. 
PCR reaction and amplification protocol for the detection 
of FLT3/TKD mutation were the same as described above 
apart from using 2.5 pmoles of each primer (Forward Primer: 
5’-6-FAM-CCGCCAGGAACGTGCTTG-3’) and (Reverse 
Primer: 5’-GCAGCCTCACATTGCCCC-3’), 6μl of the PCR 
product were then digested with 3u EcoRV at 38°C overnight. 
Fragment analysis was performed as described above. FLT3wt 
Table 1. Patients characteristics (N=94)
N (%)
Gender
Female 37 (39.4)
Male 57 (60.6)
Age, mean (SD) 57.6 (15.0)
Ht%, mean (SD) 29.2 (7.2)
WBC, median (IQR) 13,290 (4,260 – 35,670)
PLT, median (IQR) 77,500 (25,000 – 127,000)
FAB classification
M0 15 (16.0)
M1 21 (22.3)
M2 10 (10.6)
M4 20 (21.3)
M5 12 (12.8)
M6 4 (4.3)
MDS 5 (5.3)
MDS RAEB I 2 (2.1)
MDS RAEB II 4 (4.3)
MDS 5q- 1 (1.1)
Genetics
AML1/ETO 5 (5.3)
CBFB-MYH11A 7 (7.4)
Karyotype
Normal 73 (77.7)
Pathological 21 (22.3)
FiguRe 1. Fragment Analysis. A. Fragments analysis of FLT3/
ITD after capillary electrophoresis. a) shows wt fragment at 328 
bp and a mutant at 388 bp. b) shows the wt fragment at 328 bp 
and a mutant at 419 bp. c) shows the wt fragment at 328 bp and 
a mutant at 367 bp. d) shows only one fragment the wt at 328 bp. 
B. Fragments analysis of FLT3/TKD after digestion and capil-
lary electrophoresis. a) shows the wt fragment at 60 bp and a 
second mutant fragment at 110bp. b) negative control which 
confirms the full digestion by the restriction enzyme. C. Frag-
ments analysis of NPM1 after capillary electrophoresis. a) shows 
the wt fragment at 171bp and a mutant at 175bp. b) has only the 
wt fragment.
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PCR product showed a sole fragment of approximately 60 
bp, after complete digestion), whereas incomplete digestion 
represented by a longer fragment 110 bp, (Figure 1) indicated 
the presence of mutation in codon 835 and 836.
The PCR mix for the detection of NPM1 mutations con-
tained 2.5 pmoles of the following primers: (Forward Primer: 
5’-PET-GATGTCTATGAAGTGTTGTGGTTCC-3’), (Re-
verse Primer: 5’-GGACAGCCAGATATCAACTG-3’). The 
Initial Denaturation step was set at 95°C for 5 minutes, 
followed by 35 cycles of denaturation at 95°C for 30 seconds, 
annealing at 60°C for 30 seconds, extension on 72°C for 45 
seconds. Final Extension was set at 60°C for 15 minutes. After 
capillary electrophoresis on 3130 Genetic Analyzer (Applied 
Biosystems) and fragment analysis the wild type fragment was 
at 171 bp and the mutated one, with a tetranucleotide insertion, 
at 175 bp (Figure 1). NPM1 mutation type was identified using 
Ipsogen NPM1 MutaScreen Kit (QIAGEN).
i M M u n O p h e n O T y p i n g
The immunophenotypic analysis was performed by 
multi-dimensional flow cytometry (MDF) with a standard-
ized panel of monoclonal antibodies on peripheral blood and 
bone marrow samples. NAVIOS™ Flow Cytometer (Beck-
man Coulter) was used. List mode files were analyzed with 
Kaluza (Flow Cytometry Analysis Software - Kaluza 1.3). In 
order to define the antigens’ expression on immature myeloid 
cells, a CD45low/dimSSlow/dim gate was used. The combinations used 
were: CD8-FITC/CD4-PE/CD3-ECD/CD22-PC5/CD45-PC7, 
CD20-FITC/CD19-PE/CD34-ECD/CD10-PC5/CD45-PC7, 
CD2-FITC/CD7-PE/CD5-ECD/CD56-PC5/CD45-PC7, 
anti-HLA-DR–FITC/CD117-PE/CD34-ECD/CD33-PC5/
CD45-PC7, CD38-FITC/CD13-PE/CD34-ECD/CD11b-PC5/
CD45-PC7, CD15-FITC/CD64-PE/CD16-ECD/CD14-PC5/
CD45-PC7, MPO-FITC/LF-PE/, CD34-ECD/CD16-PC5/
CD45-PC7. CD135-PE, anti/, Nucleophosmin Antibody A- Dy-
Light488 marker was defined as positive when it was expressed 
on >20% in the gate of CD45low/dimSSlow/dim.40,41 PMT settings 
and compensation were kept stable throughout the study by 
using appropriate quality control beads, so that antigen MFIs 
were comparable between cases.
S T A T i S T i C A l  A n A ly S i S
Normal distributed variables were expressed as mean ± 
standard deviation; while variables with skewed distribution 
were expressed as median (interquantile range). Qualitative 
variables were expressed as absolute and relative frequencies. 
For the comparison of proportions chi-square and Fisher’s 
exact tests were used. Mann-Whitney and Wilcoxon tests were 
used for the comparison of continuous variables between two 
or more groups respectively. All reported p values are two-
tailed. Statistical significance was set at p<0.05 and analyses 
were conducted using SPSS statistical software (version 22.0).
R e S u l T S
M O l e C u l A R  A n d  i M M u n O p h e n O T y p e 
R e S u l T S
NPM1 mutations was positive in 36.2% of the AML 
patients, while FLT3/ITD and FLT3/TKD were present in 
18 (19.1%) and 10 (10.6%) of the cases (FLT3 mutations in 
29.7% in total) respectively (Table 2). At least one mutation 
was recorded in 46.8% of the patients. Both NPM1 and FLT3/
ITD mutations were present in 13,8% of the patients while 
5,3% of them had NPM1 and FLT3/TKD mutation.
Both mutations were present in much higher percentage 
in AML compared to MDS patients as only one MDS case 
was found positive for NPM1 and one for FLT3/ITD that 
progressed to AML. Table 2 shows NPM1 and FLT3 status 
of the patients.
All patients had a full immunophenotypic profile concern-
ing all the aforementioned markers. Immature cells were found 
CD34+ in 40 (42.6%) of all patients with a mean percentage 
of 77.9±26.0 in the CD45 low/SSlow gate, CD117+ in 74 
(79.6%) patients, HLADR+ in 84 (89.4%) patients, CD33 in 
75 (79.8%) patients, CD13 in 67 (71.3%), CD38 in 86 (91.5%), 
CD11b in 39 (41.5%) patients. Antigens’ MFIs as well as 
CD34+ and CD34+CD117+ percentages are presented in 
Tables 3 and the qualitative results regarding expression or 
no expression of the markers are presented in Tables 4 and 5.
CD2, CD7, CD56, CD19, CD22 aberrant positivity was 
investigated in all cases. Only 17(18%) were found positive 
for CD7, 5 (5.3%) for CD19, 7 (7.4%) positive for CD56 and 
2 (2.1%) for CD2. One case was found positive for both CD7 
and CD56. No aberrant positivity was found in the MDS cases.
C O M pA R i S O n  O F  M O l e C u l A R  
T O  i M M u n O p h e n O T y p i C  R e S u l T S
Statistically significant lower values of CD34 and 
CD34+CD117+ percentages in the immature cells’ gate, 
as well as lower CD34, CD117 and HLA-DR MFIs, and 
higher CD33 and CD11b MFIs were found in NPM1 positive 
patients (Table 3). In addition, significantly lower values of 
CD34+CD117+ percentages in the immature cells’ gate, lower 
CD34, CD117, and HLADR MFIs were found in FLT3/ITD 
positive patients (Table 3).
In patients with FLT3/TKD presence (Table 3) lower 
values of MPO MFI and higher incidence of aberrant CD7 
positivity were noted (Table 5). 
Higher percentage of immature myeloid cells and lower 
values of CD34, HLADR, and MPO MFI were noted in pa-
tients with mutated FLT3 status (data not shown).
The combined positivity of NPM1 with FLT3/ITD or FLT3/
TKD has given lower values of CD34, CD117, HLADR, CD33 
and MPO MFI as well as CD34+CD117+ percentages in the 
immature cells’ gate but the combination of NPM1, FLT3/ITD 
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Table 2. Molecular profile of the patients
Total patients N=94 N %
NPM1 PCR Positive 34 36.2
Negative 60 63.8
NPM1 subtype A 27 28.7
B 2 2.1
D 4 4.3
Not genotyped 1 1.1
FLT3/ITD Positive 18 19.1
Negative 76 80.9
MUT/WT%, average (SD)median 64.3 (30.2) 65.3 (45.4 - 84.9)
FLT3/TKD Positive 10 10.6
Negative 84 89.4
MUT/WT%, average (SD) median 23.19 (43.5) 16.4 (12.8 – 45.1)
NPM1 or/and FLT3/ITD or/and FLT3/TKD Negative 50 53.2
Positive 44 46.8
FLT3/ITD or/and FLT3/TKD Negative 67 71.3
Positive 27 28.7
NPM1 and FLT3/ITD Negative 81 86.2
Positive 13 13.8
NPM1 and FLT3/TKD Negative 89 94.7
Positive 5 5.3
NPM1 mutation detected to 36,2% of patients. FLT3/ITD mutation at 19,1% of the patients and FLT3/TKD at 10,6%. 46,8% of the patients had 
one of the mutations, while the 28,7% had FLT3/ITD or FLT3/TKD. The 13,8% of the patients had both NPM1 and FLT3/ITD mutation while the 
5,3% had NPM1 and FLT3/TKD mutation.
values of CD34 (p=0.009), CD34+CD117+(p=0.001) posi-
tivity were found in MDS as compared to AML in the gate 
of immature cells as generally most immature cells in MDS 
are CD34+CD117+. It should be noted that in the case of 
FLT3/ITD positive MDS patient immature myeloid cells were 
CD34-CD117+.
d e T e C T i O n  O F  N P M 1  A n d  F LT 3 / i T d 
M u T A T i O n S  B y  F l O w  C y T O M e T R y
NPM1 mutations were studied by FC using intracellular 
staining with Nucleophosmin MAb (NPMAb). The MFI 
of Nucleophosmin expression was studied in the gate of 
CD45low/dimSSlow/dim and it was compared to NPMAb expres-
sion of neutrophiles and lymphocytes as determined by their 
CD45/SS characteristics. An immature myeloid population was 
considered positive for NPM1 when its MFI was higher than 
the MFI of neutrophils or lymphocytes as internal negative 
controls. In addition, FLT3/ITD mutations were studied by FC 
and FLT3/TKD showed higher number of immature myeloid 
cells and only higher expression of CD11b (Tables 4, 5).
After the classification of patients as positive or negative 
for each particular antigen a significantly lower proportion of 
CD34, HLADR positive cases was found in those with posi-
tive NPM1 compared to those being positive in at least one 
of the NPM1, FLT3/ ITD and FLT3/TKD mutations (Tables 
4-5). Also, the proportion of CD33, CD11b and CD64 positive 
cases was significantly higher in those with positive NPM1 as 
compared with those with negative NPM1 and in those being 
positive for at least one of the NPM1, FLT3/ITD and FLT3/
TKD mutations as compared to the negative ones. In addition, 
CD7 positivity was significantly associated with FLT3/TKD 
positivity (Table 5). It should be noted that all cases positive 
for NPM1 and/or FLT3 mutations showed no aberrant expres-
sion of CD56 nor CD2. 
Concerning MDS cases it is not possible to compare flow 
cytometry results with molecular markers. Significantly greater 
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using surface staining with CD135 MAb. The MFI of CD135 
expression was also studied in the gate of CD45low/dimSSlow/dim 
and it was compared to CD135 expression of neutrophils and 
lymphocytes as determined by their CD45/SS characteristics. 
An immature myeloid population was considered positive for 
FLT3/ITD when its MFI was higher than the MFI of neutro-
phils or lymphocytes as internal negative controls. The results 
of the detection of NPM1 and FLT3/ITD by flow cytometry 
are presented at Table 6. No statistically significant differences 
of NPMAb MFIs were found between positive and negative 
NPM1 patients and no statistically significant differences of 
CD135 MFIs were found between positive and negative FLT3 
patients (Table 6). In fact, NPM1 and FLT3/ITD positivity 
does not seem to be detectable by FC at least using these two 
monoclonal antibodies (Figure 3). 
d i S C u S S i O n
Ιn patients with newly diagnosed AML it is very important 
to have a rapid diagnosis of the exact leukemia type as well 
as the molecular abnormalities present, so that prognostic 
information is acquired and treatment options are discussed 
as soon as possible.
Multiparameter immunophenotypic information is one 
of the first results obtained when a new acute leukemia case 
is investigated. The aim of this study was to offer as much 
information as possible to the molecular biology lab and to 
the clinical hematologists at the time of diagnosis.
To this purpose a flow cytometry method was developed 
in order to investigate the mutated genes’ protein expression 
on the surface of immature myeloid cells and to compare it 
with the molecular studies’ results. Similar methods have been 
reported in the literature where it seems that flow cytometry 
successfully detects NPM1 mutation.42-44 However, our effort 
was not successful. Even with a different monoclonal antibody 
(commercially available) the comparison with internal negative 
controls or with healthy controls has not offered any useful 
information. It should be noted that successful detection was 
performed in cell lines and in AML patients using variable ap-
proaches that are not routinely used in flow cytometry labs.42-44 
The detection of FLT3/ITD mutation was not achieved using 
CD135 by our group but this was in accordance with the results 
of a similar study in pediatric AML samples.45
Therefore, the MFIs of usual immunophenotypic mark-
ers were used in order to predict the presence of NPM1 and 
FLT3 mutations. Patients with low or no expression of more 
immature cells markers such as CD34, CD117, HLA-DR and 
higher expression of more mature markers such as CD11b 
were found positive for NPM1 mutation. A higher expression 
Table 4. Qualitative results of cytometry in association with NPM1 and FLT3/ITD status
 
NPM1
P
FLT3/ITD
PPositive N=34 Negative N=60 Positive N=18 Negative N=76
Positive N (%) N (%) N (%) N (%)
CD34 2 (5.9) 38 (63.3) <0.001* 2 (11.1) 38 (50.0) 0.003*
CD117 24 (70.6) 50 (84.7) 0.103* 14 (77.8) 60 (80.0) 1.000**
HLADR 26 (76.5) 58 (96.7) 0.004** 14 (77.8) 70 (92.1) 0.094**
CD33 33 (97.1) 42 (70.0) 0.002* 17 (94.4) 58 (76.3) 0.109**
CD38 33 (97.1) 53 (88.3) 0.251* 17 (94.4) 69 (90.8) 1.000**
CD13 23 (67.6) 44 (73.3) 0.637** 12 (66.7) 55 (72.4) 0.773*
CD11b 20 (58.8) 19 (31.7) 0.010* 9 (50.0) 30 (39.5) 0.437*
CD64 15 (44.1) 12 (20.0) 0.013* 6 (33.3) 21 (27.6) 0.773*
CD14 8 (23.5) 11 (18.3) 0.547* 3 (16.7) 16 (21.1) 1.000**
MPO 20 (62.5) 40 (71.4) 0.387* 12 (70.6) 48 (67.6) 0.813*
CD7 7 (21.2) 10 (17.5) 0.668* 5 (27.8) 12 (16.7) 0,318**
CD19 4 (11.8) 1 (1.7) 0.056** 2 (11.1) 3 (3.9) 0.243**
*Pearson’s chi-square test; **Fisher’s exact test
Patients positive for NPM1 mutation were found positive for CD34, HLADR at a significantly lower percentage in comparison with patients without 
this mutation. On the contrary they were positive for CD33, CD11b και CD64 at a significantly higher percentage. In addition, patients positive for 
FLT3/ITD mutation were found positive for CD34 at a significantly lower percentage.
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of CD33 should be mentioned as well. 
 In patients with low or no expression of CD34, CD117, 
HLADR FLT3 mutations were detected. These results are in 
accordance with other studies.41-47 Simultaneous presence of 
both NPM1 and FLT3/ITD or FLT3/TKD mutations, but not 
with the three of them together was found in patients with low 
or no expression of CD34, CD117 and HLA-DR. 
To our knowledge, such an association with the combina-
tion of mutations has not been reported in the literature. The 
combination of the three mutations seems to be associated 
only with higher expression of CD11b. Higher CD11b ex-
pression was correlated with poor prognosis in the group of 
patients who lacked cytogenetic and molecular aberrancies41 
and the combination of the three mutations is also linked to 
poor prognosis.
The presence of CD7 aberrant lymphoid markers expres-
sion was found in patients with FLT3 but not NPM1 mutations. 
CD56 or CD2 positivity was found only in negative cases for 
NPM1 and/or FLT3 mutations.
The rare case of CD34 negative MDS was found positive 
for FLT3/ITD mutation and progressed to AML. This should 
be taken into account in the study of MDS cases.
In conclusion flow cytometry detection of common phe-
notypic markers in AML offers some indications about the 
presence of NPM1 and FLT3 mutations linked to prognosis, 
Table 5. Qualitative results of cytometry in association with FLT3/TKD status and combination of NPM1, FLT3/ITD 
and FLT3/TKD
FLT3/TKD
P
NPM1or/and FLT3/ ITD  
or/and FLT3/TKD
P
Positive N=10 Negative N=84 Positive N=18 Negative N=76
Positive N (%) N (%) N (%) N (%)
CD34 4 (40.0) 36 (42.9) 1.000** 8 (18.2) 32 (64.0) <0.001*
CD117 8 (80.0) 66 (79.5) 1.000** 32 (72.7) 42 (85.7) 0.121*
HLADR 9 (90.0) 75 (89.3) 1.000** 35 (79.5) 49 (98.0) 0.005**
CD33 8 (80.0) 67 (79.8) 1.000** 41 (93.2) 34 (68.0) 0.002*
CD38 10 (100.0) 76 (90.5) 0.539** 43 (97.7) 43 (86.0) 0.063**
CD13 9 (90.0) 58 (69.0) 0.272** 29 (65.9) 38 (76.0) 0.281*
CD11b 6 (60.0) 33 (39.3) 0.310** 24 (54.5) 15 (30.0) 0.016*
CD64 5 (50.0) 22 (26.2) 0.144** 18 (40.9) 9 (18.0) 0.014*
CD14 4 (40.0) 15 (17.9) 0.113** 11 (25.0) 8 (16.0) 0.278*
MPO 5 (50.0) 55 (70.5) 0.278** 25 (59.5) 35 (76.1) 0.096*
CD7 in positive cases 6 (60.0) 11 (13.8) 0.003** 11 (25.6) 6 (12.8) 0.121*
CD19 in positive cases 1 (10.0) 4 (4.8) 0.438** 4 (9.1) 1 (2.0) 0.182**
*Pearson’s chi-square test; **Fisher’s exact test
No significant differences were detected between patients positive or negative for FLT3/TKD mutation. Patients with at least one mutation were 
found positive for CD34 and HLADR at a significantly lower percentage in comparison with patients without any mutation and they were positive 
for CD33, CD11b και CD64 at a significantly higher percentage. Patients positive for FLT3/TKD mutation were found positive for CD7 at a 
significantly higher percentage in comparison with patients without this mutation.
FiguRe 2. Presence of NPM1, FLT3/ITD, FLT3/TKD and FlT3 
in total samples. Statistically significant lower percentages of 
CD34+, CD34+CD117+ percentages were found in NPM1(+) 
cases in comparison to NPM1(-) cases. Statistically significant-
NPM1 positivity and with lower expression of NPM1 on neutro-
phils cells and lymphocytes.
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as well as certain aberrant lymphoid markers’ positivity seems 
to be linked with the presence or absence of these molecular 
markers.
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